...
search icon
rlyb-img

Rallybio Corp, Common Stock

RLYB

NSQ

$0.8685

+$0.01

(1.16%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$34.63M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
195.89K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-1.67
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.82 L
$3.46 H
$0.8685

About Rallybio Corp, Common Stock

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameRLYBSectorS&P500
1-Week Return-1.3%-0.46%0.38%
1-Month Return-14.01%5.69%1.64%
3-Month Return-14.85%0.07%5.64%
6-Month Return-26.4%0.03%16.44%
1-Year Return-30.52%3.12%22.25%
3-Year Return-93.81%10.61%34.76%
5-Year Return-93.84%46.81%85.78%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue26.34K62.03K109.00K167.00K150.00K[{"date":"2019-12-31","value":15.77,"profit":true},{"date":"2020-12-31","value":37.14,"profit":true},{"date":"2021-12-31","value":65.27,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":89.82,"profit":true}]
Gross Profit(26.34K)(62.03K)(109.00K)(167.00K)(150.00K)[{"date":"2019-12-31","value":-2634400,"profit":false},{"date":"2020-12-31","value":-6203000,"profit":false},{"date":"2021-12-31","value":-10900000,"profit":false},{"date":"2022-12-31","value":-16700000,"profit":false},{"date":"2023-12-31","value":-15000000,"profit":false}]
Gross Margin(Infinity%)(Infinity%)(Infinity%)(Infinity%)(Infinity%)[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}]
Operating Expenses17.64M25.30M45.65M67.88M78.93M[{"date":"2019-12-31","value":22.35,"profit":true},{"date":"2020-12-31","value":32.06,"profit":true},{"date":"2021-12-31","value":57.83,"profit":true},{"date":"2022-12-31","value":86,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(17.64M)(25.30M)(45.65M)(67.88M)(78.93M)[{"date":"2019-12-31","value":-1764200000,"profit":false},{"date":"2020-12-31","value":-2530300000,"profit":false},{"date":"2021-12-31","value":-4564800000,"profit":false},{"date":"2022-12-31","value":-6788400000,"profit":false},{"date":"2023-12-31","value":-7893200000,"profit":false}]
Total Non-Operating Income/Expense340.00K485.00K184.00K4.27M10.14M[{"date":"2019-12-31","value":3.35,"profit":true},{"date":"2020-12-31","value":4.78,"profit":true},{"date":"2021-12-31","value":1.81,"profit":true},{"date":"2022-12-31","value":42.1,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(17.46M)(24.94M)(45.51M)(65.58M)(74.56M)[{"date":"2019-12-31","value":-1746000000,"profit":false},{"date":"2020-12-31","value":-2494000000,"profit":false},{"date":"2021-12-31","value":-4550800000,"profit":false},{"date":"2022-12-31","value":-6557900000,"profit":false},{"date":"2023-12-31","value":-7456400000,"profit":false}]
Income Taxes166.00K(15.00K)1.50M908.00K(2.04M)[{"date":"2019-12-31","value":11.05,"profit":true},{"date":"2020-12-31","value":-1,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":60.45,"profit":true},{"date":"2023-12-31","value":-135.89,"profit":false}]
Income After Taxes(17.63M)(24.93M)(47.01M)(66.49M)(72.52M)[{"date":"2019-12-31","value":-1762600000,"profit":false},{"date":"2020-12-31","value":-2492500000,"profit":false},{"date":"2021-12-31","value":-4701000000,"profit":false},{"date":"2022-12-31","value":-6648700000,"profit":false},{"date":"2023-12-31","value":-7252300000,"profit":false}]
Income From Continuous Operations(17.56M)(26.45M)(45.51M)(65.58M)(70.53M)[{"date":"2019-12-31","value":-1756300000,"profit":false},{"date":"2020-12-31","value":-2644700000,"profit":false},{"date":"2021-12-31","value":-4550800000,"profit":false},{"date":"2022-12-31","value":-6557900000,"profit":false},{"date":"2023-12-31","value":-7052500000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(17.63M)(24.93M)(47.01M)(66.49M)(74.56M)[{"date":"2019-12-31","value":-1762600000,"profit":false},{"date":"2020-12-31","value":-2492500000,"profit":false},{"date":"2021-12-31","value":-4701000000,"profit":false},{"date":"2022-12-31","value":-6648700000,"profit":false},{"date":"2023-12-31","value":-7456400000,"profit":false}]
EPS (Diluted)(1.97)(4.11)(7.70)(2.11)(1.84)[{"date":"2019-12-31","value":-197.13,"profit":false},{"date":"2020-12-31","value":-411.2,"profit":false},{"date":"2021-12-31","value":-770,"profit":false},{"date":"2022-12-31","value":-211,"profit":false},{"date":"2023-12-31","value":-184,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

RLYB
Cash Ratio 9.18
Current Ratio 9.55

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

RLYB
ROA (LTM) -38.54%
ROE (LTM) -67.39%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

RLYB
Debt Ratio Lower is generally better. Negative is bad. 0.10
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.90

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

RLYB
Trailing PE NM
Forward PE NM
P/S (TTM) 59.66
P/B 0.50
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Rallybio Corp share price today?

Rallybio Corp (RLYB) share price today is $0.8685

Can Indians buy Rallybio Corp shares?

Yes, Indians can buy shares of Rallybio Corp (RLYB) on Vested. To buy Rallybio Corp from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RLYB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Rallybio Corp be purchased?

Yes, you can purchase fractional shares of Rallybio Corp (RLYB) via the Vested app. You can start investing in Rallybio Corp (RLYB) with a minimum investment of $1.

How to invest in Rallybio Corp shares from India?

You can invest in shares of Rallybio Corp (RLYB) via Vested in three simple steps:

  • Click on Sign Up or Invest in RLYB stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Rallybio Corp shares
What is Rallybio Corp 52-week high and low stock price?

The 52-week high price of Rallybio Corp (RLYB) is $3.46. The 52-week low price of Rallybio Corp (RLYB) is $0.82.

What is Rallybio Corp price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Rallybio Corp (RLYB) is 0.50

What is the Market Cap of Rallybio Corp?

The market capitalization of Rallybio Corp (RLYB) is $34.63M

What is Rallybio Corp’s stock symbol?

The stock symbol (or ticker) of Rallybio Corp is RLYB

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top